Psychedelic Funding, Public Markets, and M&A in 2025 Post published:January 20, 2026 Post category:Analysis/Pα+
Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions Post published:January 15, 2026 Post category:2025 Year in Review/Analysis/News/Pα+
2025 Year in Review: Future(s) & Open Questions (Video) Post published:January 6, 2026 Post category:2025 Year in Review/Analysis/News/Pα+
2025 Year in Review: 10 Standout Stories in Psychedelics Post published:January 2, 2026 Post category:2025 Year in Review/Analysis/News
2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video) Post published:December 30, 2025 Post category:2025 Year in Review/Analysis/News/Pα+
2025 Year in Review: Psychedelics in 2025 (Video) Post published:December 23, 2025 Post category:2025 Year in Review/Analysis/News/Pα+
The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon Post published:December 3, 2025 Post category:Analysis/News/Pα+
ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics Post published:November 22, 2025 Post category:Analysis/News/Pα+
AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3 Post published:November 10, 2025 Post category:Analysis/News/Pα+
Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months Post published:November 4, 2025 Post category:Analysis/News/Pα+